This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Markovic, D. Articles by Grammatopoulos, D. K. Search for Related Content PubMed PubMed Citation Articles by Markovic, D. Articles by Grammatopoulos, D. K.

The Onset of Labor Alters Corticotropin-Releasing Hormone Type 1 Receptor Variant Expression in Human Myometrium: Putative Role of Interleukin-1ß

Endocrinology and Metabolism (D.M., M.V., M.G., D.S., H.L., D.K.G.), Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; and Department of Pharmacology and Therapeutics (R.N.), Institute of Infection, Immunity, and Inflammation, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1

Address all correspondence and requests for reprints to: Prof. D. K. Grammatopoulos, Sir Quinton Hazell Molecular Medicine Research Centre, Warwick Medical School, The University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, United Kingdom. E-mail: d.grammatopoulos{at}warwick.ac.uk.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
CRH targets the human myometrium during pregnancy. The efficiency of CRH actions is determined by expression of functional receptors (CRH-R), which are dynamically regulated. Studies in myometrial tissue biopsies using quantitative RT-PCR demonstrated that the onset of labor, term or preterm, is associated with a significant 2- to 3-fold increase in CRH-R1 mRNA levels. Detailed analysis of myometrial CRH-R1 mRNA variants showed a decline of the pro-CRH-R1 mRNA encoding the CRH-R1ß variant during labor and increased mRNA levels of CRH-R1d mRNA. Studies in myometrial cells identified IL-1ß as an important regulator of myometrial CRH-R1 gene expression because prolonged treatment of myometrial cells with IL-1ß (1 ng/ml) for 18 h induced expression of CRH-R1 mRNA levels by 1.5- to 2-fold but significantly attenuated CRH-R1ß mRNA expression by 70%. In contrast, IL-1ß had no effect on CRH-R1d mRNA expression. Studies using specific inhibitors suggest that ERK1/2, p38 MAPK, and downstream nuclear translocation of nuclear factor-B mediate IL-1ß effects on myometrial CRH-R1 gene. However, the increased CRH-R1 mRNA expression was associated with a dampening of the receptor efficacy to activate the adenylyl cyclase/cAMP signaling cascade. Thus, our findings suggest that IL-1ß is an important regulator of CRH-R1 expression and functional activity, and this interaction might play a role in the transition of the uterus from quiescence to active contractions necessary for the onset of parturition.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
DURING GESTATION, THE uterus remains in a state of quiescence while the fetus matures. At term, delivery is facilitated by cervical dilatation and a switch of the uterus from quiescence to a state of coordinated contractility (1). In humans, the mechanism of parturition involves multiple pathways, and some are regulated by "stress" peptides, in particular placental CRH. The plasma concentrations of CRH increase exponentially as pregnancy progresses toward labor and may act as a predictor of the duration of human gestation (2).

The precise biological function of CRH and the family of CRH-related peptides, urocortins, during pregnancy are not well defined, but they appear to play important roles in regulation of myometrial contractility (3). The human myometrium expresses a plethora of CRH and CRH-related peptides and their respective receptors R1 and R2 (4). Current evidence suggests that CRH-R1- and CRH-R2-activated signaling pathways might exert distinct actions in the regulation of myometrial contractility (4). The myometrial CRH-Rs exhibit increased affinity for CRH during pregnancy (5) and, on agonist activation, stimulate cAMP and cGMP production and nitric oxide synthase up-regulation (6), thus promoting myometrial quiescence, possibly though activation of CRH-R1 receptors. Recent isometric contractility studies in myometrial tissue strips have confirmed the ability of CRH to relax the human pregnant myometrium (7). In contrast, CRH-R2-specific agonists such as urocortin-II can activate ERK1/2 and RhoA pathways that actively promote myometrial contractility (8). Furthermore, progression of human pregnancy toward term and active labor is associated with activation of intracellular mechanisms involving uterotonin-activated protein kinase C that reduce the myometrial responsiveness to CRH, an effect mediated through phosphorylation and desensitization of specific CRH-R variants (9, 10).

The human CRH-R1 gene spans over a 50.3-kb region and contains 14 exons (11); translation of all exons results in a human-specific, 444-amino acid seven-transmembrane domain protein receptor, termed CRH-R1ß, which exhibits impaired agonist binding and signaling properties. Deletion of exon 6 results in expression of CRH-R1 mRNA, which is the main functional CRH-R1 receptor variant and contains 415 amino acids. Therefore, the CRH-R1ß can be considered as a "pro-CRH-R1" receptor variant. The CRH-R1 gene appears to be subject to significant alternative splicing, and a growing number of CRH-R1 mRNA splice variants have been described, termed R1c–R1n (11). All of these variants have exon 6 spliced out together with other deletions. At least four distinct CRH-R1 mRNA variants (, ß, c, and d) have been identified in human myometrium during pregnancy (12); progression toward term is associated with altered expression of myometrial CRH-Rs and the appearance of CRH-R1 variants such as the R1d, with reduced signaling abilities (13). This might have important functional consequences by dampening tissue responsiveness to CRH actions.

The mechanisms regulating myometrial CRH-R1 expression are not well understood. The CRH-R1 promoter contains, among others, nuclear factor-B (NF-B) putative recognition elements (Bs) elements (14). Accumulating evidence points toward a role for NF-B and its major activator IL-1ß in the physiology and pathophysiology of labor (15), because myometrial IL-1ß and NF-B activity increases with labor onset and is central to multiple prolabor pathways by stimulating prostaglandin-endoperoxide synthase 2 (PTGS2) expression and prostaglandin (PG) synthesis (16). In this study, we examined the levels of expression of CRH-R1 and specific CRH-R1 variants by using quantitative RT-PCR analysis from myometrial biopsies obtained preterm and term, before and after the onset labor as well as the regulation of CRH-R1 expression and activity by IL-1ß in human pregnant myometrial cells.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Subjects and myocytes culture preparations
Pregnant myometrial biopsies were obtained from women undergoing elective cesarean section preterm (30–35 wk of gestation; n = 12) or at term (>37 wk of gestation; n = 12) before (n = 6) or after (n = 6) the onset of labor for nonmaternal problems. Active labor was demonstrated by regular uterine contractions and ripe cervix, with dilation more than 4 cm (range of 4–7 cm; mean of 5.4 cm). The biopsy site was standardized to the upper margin of the lower segment of the uterus in the midline. This provides the closest approximation to the upper segment of the uterus. The biopsies were immediately snap frozen in liquid nitrogen and subsequently stored at –70 C until use or processed immediately for myocyte cell culture as described previously (10). The age range was 25–35 yr for both groups. Ethical approval was obtained from the local ethical committee, and informed consent to the study was obtained from all patients.

The myometrial smooth muscle cells were cultured in DMEM containing 10% fetal calf serum, 1% L-glutamine, 200 IU/ml penicillin, 200 mg/ml streptomycin, at 37 C in a humidified atmosphere of 95% air and 5% CO₂ until confluency. Cells were trypsinized in 0.25% trypsin containing 0.02% EDTA in Hanks’ balanced salt solution and cultured in 12-well plates for protein and in six-well plates for mRNA extraction. At 18 h before treatments, the cells were transferred in DMEM without L-glutamine, fetal calf serum, and antibiotics. The following day, cells were treated with IL-1ß (1 ng/ml) for various time intervals (2–18 h). In some experiments, cells with pretreated with or without specific inhibitors, as follows: 10 µM U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene] (2 h) [U0126 inhibits both active and inactive MAPK kinase (MEK1/2)], 10 µM SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole] (1 h) (SB203580 is a selective inhibitor of p38 MAPK, which acts by competitively inhibiting ATP binding), 25 µM IB kinase (IKK) inhibitor II, Wedelolactone (4 h) (IKK inhibitor II is a selective and irreversible inhibitor of IKK and ß kinase activity; it inhibits NF-B-induced gene transcription by blocking the phosphorylation and degradation of IB). Proteins and RNA were harvested as described below. For confocal microscopy experiments, serum-deprived cells were stimulated with 1 ng/ml IL-1ß for 30 and 60 min. The purity of myometrial muscle cells was assessed by immunocytochemical staining for -actin with mouse monoclonal antibody specific for smooth muscle -actin (Sigma, Gillingham, UK). Confluent cells up to third passage were used; no significant difference between results were obtained with cells from individual passages and cells obtained from different myometrial biopsies.

Chemicals
CRH was purchased from Bachem (Merseyside, UK). IL-1ß and the inhibitors (U0126, MEK1/2 inhibitor; SB203580, p38 inhibitor; and IKK inhibitor II, Wedelolactone) were from Merck Biosciences (Nottingham, UK). Antibodies (CRH-R, p65, IB, and PTGS2) were from Santa Cruz Biotechnology (Santa Cruz, CA); glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was from BioGenesis (Bournemouth, UK); secondary antibodies were from DakoCytomation (Eye, UK); Alexa Fluor594, Alexa Fluor488-phalloidin, and Slowfade gold antifade reagent with 4',6'-diamidino-2-phenylindole (DAPI) were from Invitrogen (Carlsbad, CA). Vectashield Hard Set TM mounting medium for fluorescence was from Vector Laboratories (Burlingame, CA). Mounting solution without DAPI was from Vector Laboratories (Peterborough, UK). Cell culture media were from Invitrogen. RNasin, avian myeloblastosis virus, random hexamers, and oligo-dTTP were from Promega (Madison, WI), and dNTPs, Taq polymerase, and DNA ladder were purchased from Bioline (London, UK). SYBR Green I and PCR mixture for quantitative PCR was from BioGene (Kimbolton, UK). Primers were purchased from TANG (Gateshead, UK). All other chemicals were purchased from Sigma.

RNA extraction and real-time and conventional RT-PCR
RNA extraction was performed by using GeneElute Mammalian Total RNA kit (Sigma), according to the instructions of the manufacturer. The purity and concentration of total RNA was determined spectroscopically. RNA, 500 ng, was used for cDNA synthesis, in a total volume of 50 µl RT reaction. Total RNA was heated up to 70 C for 5 min before the addition of random hexamers (Promega) and reverse transcriptase containing an RNase inhibitor (Fermentas, York, UK). The reaction mixture was incubated at 42 C for 60 min, followed by an additional 10 min incubation at 70 C.

Quantitative (real-time) PCR of PTGS2 was performed on a Roche Light Cycler system (Roche Molecular Biochemicals, Mannheim, Germany). The PCR was performed in a 10 µl reaction mixture containing 5 µl of PCR 2x Mastermix with 2 mM MgCl₂, 0.5 µl of Light Cycler DNA Master SYBR Green I, 1 µl of each primer (2 ng/µl), and 1 µl of cDNA. The PCR protocol consisted of a denaturation step at 95 C for 15 sec, followed by 40 cycles of amplification at 95 C for 5 sec, 58 C for 10 sec, and 72 C for 15 sec, and finally by a melting-curve analysis step at 95 C for 0 sec, 56 C for 15 sec, and 99 C for 0 sec. For analysis, quantitative amounts of gene of interest were standardized against the housekeeping gene ß-actin. The sequence of PTGS2 mRNA primers used were as follows: forward, 5'-TTCAAATGAGATTGTGGGAAAATTGCT-3'; and reverse, 5'-AGATCATCTCTGCCTG AGTATCTT-3'. The ß-actin primers were as follows: forward, 5'-AAGAGAGGCATCCTCACCCT-3'; and reverse, 5'-TACATGGCTGGGGTGTTGAA-5'. As negative controls, preparations lacking RNA or reverse transcriptase were used. RNA expression was tested in four independent experiments. The mRNA levels were expressed as a ratio, using the " method" for comparing relative expression between treatments. The PCR products were sequenced in an automated DNA sequencer (Department of Biological Sciences, The University of Warwick, Warwick, UK), and the sequence data were analyzed using Blast Nucleic Acid Database Searches from the National Center for Biotechnology Information.

Quantitative PCR on a TaqMan Gene Expression Assay (Applied Biosystems, Warrington, UK) was also used to determine expression levels of various CRH-R1 mRNA variants in human gestational myometrium and human primary myometrial cells. Briefly, four sets of oligonucleotide primers and four TaqMan probes specific for various human CRH-R1 mRNAs were designed from the GenBank database by mySciences (Applied Biosystems). The first primers/probe combination used amplified a sequence overlapping exons 8–9, which is present in all known CRH-R1 variants detected in the human myometrium, R1, R1ß, R1c, and R1d (12). Therefore, the PCR product reflected total CRH-R1 mRNA variant expression and was designated as CRH-R1_T. In addition, primers and fluorescent probes specific for exon 6 (found in R1ß mRNA variant only) were designed, and the PCR amplification product was designated as CRH-R1ß. Similarly, primers and probes overlapping exons 2–4 and 12–14 were designed to amplify sequences specific for CRH-R1c and CRH-R1d (Fig. 1). Real-time RT-PCRs were performed using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems) in a total volume of 30 µl reaction mixture following the protocol of the manufacturer, using the SYBR Green Universal 2x PCR Master Mix (Applied Biosystems) and 0.1 µM of each primer using the dissociation protocol for the amplification of CRH-R1 mRNA variants. Negative controls containing water instead of first-strand cDNA were also used. Each sample was normalized on the basis of its 18S ribosomal RNA content (housekeeping gene). The 18S quantification was performed with a TaqMan ribosomal RNA reagent kit (Applied Biosystems) using the protocol of the manufacturer. All samples were run in triplicate, and results were calculated with reference to the amplification of 18S rRNA using comparative threshold cycle (C_T) method for relative quantitation (ABI Prism 7000 SDS version 1.1 software; Applied Biosystems).

View larger version (18K): [in this window] [in a new window]   FIG. 1. Schematic diagram of CRH-R1 gene splicing pattern and the annealing position of PCR primers and real-time PCR probes relative to the structure of CRH-R1 alternative spliced variants. Arrows indicate annealing position of primers. The qualitative RT-PCR forward primer was designed to span across exons 3 and 4; thus, annealing to CRH-R1c sequence was not possible.

–(CT sample –

CT calibrator)

Qualitative RT-PCR analysis
The conditions for the conventional (qualitative) RT-PCR of CRH-R1 mRNA were as follows: 95 C for 15 sec, 64 C for 15 sec, and 72 C for 30 sec, in a total of 35 cycles with a final extension step at 72 C for 7 min. Primers sequence were as follows: forward, 5'-CAAACAATGGCTACCGGGAG-3'; and reverse, 5'ACACCCCAGCCAATGCAGA-3'. These primers amplified a 475-bp DNA fragment present in all CRH-R1 mRNA variants except CRH-R1ß and a 538-bp DNA fragment specific for CRH-R1ß. Ten microliters of the reaction mixture were subsequently electrophoresed on a 1.2% agarose gel and visualized by ethidium bromide, using a 1-kb DNA ladder (Invitrogen) to estimate the band sizes. As a negative control for all of the reactions, distilled water was used in place of the cDNA. The PCR products were sequenced in an automated DNA sequencer (Department of Biological Sciences, The University of Warwick), and the sequence data were analyzed using Blast Nucleic Acid Database Searches from the National Center for Biotechnology Information.

Western blot
Cells were lysed in 150 µl Laemmli’s buffer. The lysates were sonicated for 30 sec, and, after boiling for 5 min, proteins were spun down and 15 µl of the supernatant was loaded on 10%SDS-polyacrylamide gels. Gels were run at 200 V for approximately 1 h. Proteins were electrophoretically transferred to a polyvinylidene difluoride filter at 100 V for 1 h. The filters was initially incubated in Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T) and 5% milk (wt/vol) for 1 h at room temperature and, after a brief wash with TBS-T, were incubated with primary antisera. The primary antibodies for PTGS2 and CRH-R1/2 were used at a 1:1000 dilution in TBS-T overnight at 4 C (CRH-R1/2) or at room temperature for 1 h (PTGS2), whereas the IB antibody was used at a 1:500 dilution (overnight at 4 C). Equal protein loading was confirmed by using anti-GAPDH antibodies (1:40,000 dilution in TBS-T at room temperature for 1 h). The filters were washed thoroughly for 30 min with TBS-T, before incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies (1:2000) for 1 h at room temperature. After an additional washing step for 30 min with TBS-T, antibody complexes were visualized using enhanced chemiluminescence. In some experiments, IB and GAPDH probed blots were incubated with goat antirabbit IRDye 800-conjugated IgG at 1:6000 in 10 ml of blocking buffer with gentle agitation for 1 h at room temperature. Finally, the blot was washed two more times each with 15 ml of TBS-T and once with TBS only. The membrane was dried, visualized, and analyzed on the Odyssey Infrared Imaging System (LI-COR Biosciences, Cambridge, UK).

Measurement of cAMP production
Myometrial cells were plated in 12-well plates, and, when they reached 70–80% confluency, they were transferred in DMEM for 12 h and treated with 1ng/ml IL-1ß for 18 h. At the end of the incubation period, media was aspirated and cells were washed with plain DMEM. Then, stimulation buffer (DMEM containing 10 mM MgCl₂ and 1 mg/ml 3-isobutyl-1-methylxanthine, a phosphodiesterase inhibitor) was added and cells were incubated for 20 min at 37 C. After washing with 1 ml DMEM, cells were stimulated with 100 nM CRH or 10 µM forskolin (to induce direct adenylyl cyclase activation) for 15 min. The reaction was stopped by adding 10 µl of concentrated HCl for 15–20 min at room temperature. Subsequently, cells were scraped and transferred in 1.5 ml tubes. After a brief spin, lysates were stored at –20 C. The cAMP levels were determined by a commercially available ELISA kit (low pH) from R & D Systems (Minneapolis, MN).

Confocal microscopy
Myocytes were grown on aminopropylethoxysilane-treated glass coverslips. To monitor NF-B(p65) translocation, serum-deprived cells were treated with 1 ng/ml IL-1ß for 30–60 min and fixed with 4% paraformaldehyde in PBS. After permeabilization with PBS containing 0.01% Triton X-100 and 3% BSA, cells were incubated with p65 antibody (1:100) overnight at 4 C. After three brief washes with PBS, slides were incubated for 1 h at room temperature with 1:400 antirabbit Alexa Fluor594. After three washes with PBS, the slides were mounted with Vectashield Hard Set TM mounting medium for fluorescence (Vector Laboratories, Burlingame, CA) or Slowfade gold antifade reagent with DAPI (Invitrogen). For detection of CRH-R, fixed cells were incubated with 1:100 CRH-R1/2 antibody overnight in the presence or absence of 1 µM blocking peptide. On the following day, the slides were washed and incubated with Alexa Fluor594 and Alexa Fluor488-phalloidin. The slides were mounted as described above. The slides were examined under an oil immersion objective (x63) using a Leica (Deerfield, IL) DMRE laser scanning confocal microscope with TCS SP2 scan head.

Data analysis and statistical methods
Results from triplicate experiments were pooled and analyzed by one-way ANOVA with Student-Newman-Keuls multiple comparison methods, using SigmaStat version 3.0 (SPSS, Chicago, IL).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Determination of myometrial CRH-R1 mRNA variant expression
Previous studies (12) using qualitative RT-PCR analysis for CRH-R1 mRNA variants identified R1, R1ß, and R1c mRNA to be present in both preterm and term pregnant myometrium, whereas R1d mRNA was only present in term myometrium. Quantitative analysis of RNA isolated from human pregnant (term and preterm) myometrium with amplified CRH-R1 (total) mRNA-specific sequences showed a low number of C_T (30–32 cycles), indicative of substantial levels of CRH-R1_T mRNA. CRH-R1ß and R1c as well as R1d were also amplified from both term and preterm myometrium (reflecting probably the higher sensitivity and specificity of the quantitative RT-PCR method used); however, the C_T values of these variants mRNA amplification were higher (33–35 cycles), suggesting lower levels of expression (data not shown). Furthermore, comparison of the mRNA concentrations showed that the expression levels of the CRH-R1 mRNA variants relative to the total CRH-R1_T mRNA levels was 4% for the R1ß, 1% for the R1c, and 20% for the R1d. These data suggest that the majority of CRH-R1_T mRNA amplification signal probably reflects CRH-R1 mRNA levels expressed in human myometrium (CRH-R1_T). These ratios cannot be used for an accurate quantitation of each CRH-R1 mRNA levels but can rather provide a relative estimation of comparative receptor variant expression.

Studies on human preterm nonlaboring, preterm laboring, term nonlaboring, or term laboring human myometrium (n = 6 for each group) showed that the expression of both CRH-R1_T and CRH-R1ß mRNAs were significantly higher (by 2.5- and 0.5-fold, respectively) in term compared with preterm nonlaboring myometrium (Fig. 2A). In contrast, CRH-R1c and R1d mRNAs were not altered (Fig. 2A). Furthermore, active labor in both preterm and term groups was associated with a significant increase (by 3- and 2-fold, respectively) of CRH-R1_T mRNA and CRH-R1d mRNA (by 2.5- and 3.5-fold, respectively). In contrast, CRH-R1ß mRNA showed a significant decrease (by 40 and 70%, respectively) in laboring myometrium (both preterm and term) compared with nonlaboring myometrium, whereas no change was observed in CRH-R1c mRNA levels (Fig. 2B).

View larger version (30K): [in this window] [in a new window]   FIG. 2. Comparative studies of expression levels of CRH-R1 mRNA variants in gestational myometrial tissues (n = 6 for each group) in relation to progression toward term (A) or the onset of labor (preterm or term) (B). Relative expression was determined by real-time quantitative RT-PCR (TaqMan; Applied Biosystems). Amplification runs in triplicate were performed with cDNA preparations reversibly transcribed in the same reaction from 500 ng total RNA in each case. Results are expressed as mean values ± SEM of relative mRNA expression levels normalized against the levels of the housekeeping gene 18S RNA. *, P < 0.05 compared with preterm nonlaboring (A) or nonlaboring (B) myometrium values. The mean results of nonlaboring preterm myometrium (A) or nonlaboring preterm and term (B) were arbitrarily assigned the value 1. NL, Nonlaboring; L, laboring.

View larger version (20K): [in this window] [in a new window]   FIG. 3. A, RT-PCR amplification of CRH-R1 variants sequences from RNA extracted from primary human myometrial cell cultures. Specific primers able to amplify CRH-R1, R1ß, and R1d mRNA were used as described in Materials and Methods. Primer sets were designed to amplify a 475-bp fragment, present in CRH-R1 and R1d (but not R1c) mRNA, or a 538-bp fragment, present in CRH-R1ß mRNA. PCR products were resolved on 1.2% agarose gel and stained with ethidium bromide. The identities of the fragments were confirmed by direct nucleotide sequencing. B and C, Visualization of CRH-R distribution in human pregnant myometrial cells by indirect immunofluorescence confocal microscopy using specific primary antibodies for CRH-R and Alexa Fluor594 secondary antibody (red) in the presence or absence of CRH-R blocking peptide (1 µM) as described in Materials and Methods. Distribution of F-actin and stress fibers was also monitored by double staining with Alexa Fluor488-phalloidin (green). Cell nuclei were stained with the DNA-specific dye DAPI (blue). Identical results were obtained from six independent experiments.

View larger version (36K): [in this window] [in a new window]   FIG. 4. Time course of the IL-1ß effect on CRH-R1 (total), CRH-R1ß, and CRH-R1d mRNA level in human myometrial smooth muscle cells. Cells isolated from myometrium of nonlaboring women (n = 6) were treated with IL-1ß (1 ng/ml) for various time intervals, and target mRNA were determined by real-time quantitative RT-PCR (TaqMan; Applied Biosystems) as described in Materials and Methods. Data are expressed as mean values ± SEM of relative mRNA expression levels normalized against 18S RNA. *, P < 0.05 compared with basal (untreated). The mean results of basal untreated mRNA concentrations were arbitrarily assigned the value 1.

View larger version (50K): [in this window] [in a new window]   FIG. 5. IL-1ß-induced activation of the NF-B pathway. A, Human smooth muscle cells isolated from myometrium of nonlaboring women (n = 6) were treated with IL-1ß (1 ng/ml) for various time intervals, and p65 (RelA) nuclear translocation was monitored by indirect immunofluorescence confocal microscopy using specific primary antibodies for p65 and Alexa Fluor594 secondary antibody (red) as described in Materials and Methods. In some experiments (C), cells were pretreated with or without 25 µM of the IKK inhibitor II Wedelolactone for 4 h, before IL-1ß addition for 1 h. Identical results were obtained from four independent experiments and at least 20 cells were examined in each experiment. B, Representative Western blots of IB expression of cells stimulated with IL-1ß (1 ng/ml) for various time intervals. After cell lysis and centrifugation, supernatants were subjected to SDS-PAGE and immunoblotted (IB) with antibodies for IB or GAPDH (protein loading control). After incubation with horseradish peroxidase-conjugated goat antirabbit antibody, complexes were visualized by enhanced chemiluminescence (top). Alternatively, immunoreactivity was detected by secondary antibodies conjugated to IRDye 800 (near-IR) and the Odyssey detection system as described in Materials and Methods (bottom). The data represent the mean ± SEM of three estimations from three independent experiments. In some experiments (bottom), cells were pretreated with or without 25 µM of the IKK inhibitor II Wedelolactone for 4 h, before IL-1ß addition for 30 min.

View larger version (24K): [in this window] [in a new window]   FIG. 6. Effect of IKK, ERK1/2, and p38 MAPK inhibitors on IL-1ß-induced effects on myometrial PTGS2 and CRH-R1 gene expression. After pretreatment of cells with Wedelolactone (A) and U0126 and SB203580 (B) and stimulation with IL-1ß (1 ng/ml) for 18 h, RNA was extracted, and PTGS2 and CRH-R1 mRNA levels were determined by real-time quantitative RT-PCR [TaqMan (Applied Biosystems) and Lightcycler (Roche Applied Science), respectively] as described in Materials and Methods. Data are expressed as mean ± SEM values of relative mRNA expression levels normalized against 18S or GAPDH RNA. *, P < 0.05 compared with inhibitor-untreated values.

Effects of IL-1ß on CRH-induced myometrial cAMP response
One of the major signaling pathways mediating CRH effects in human myometrial cells involves activation of the G_s-adenylyl cyclase pathway (20). The functional consequences of IL-1ß-induced myometrial CRH-R1 up-regulation was investigated by pretreatment of cells with IL-1ß for 18 h, followed by determination of intracellular cAMP production in response to CRH stimulation. Surprisingly, although IL-ß-treatment increased basal and forskolin-stimulated cAMP levels (by 10- and 2-fold, respectively), it significantly impaired CRH-induced cAMP production (by 85 ± 7%), suggesting that myometrial CRH-R1 mRNA and protein up-regulation was not associated with increased functional activity and cAMP production (Fig. 7).

View larger version (22K): [in this window] [in a new window]   FIG. 7. Effect of IL-1ß on CRH-induced cAMP production from human pregnant myometrial cells. Cells were pretreated with IL-1ß (1 ng/ml) for 18 h, followed by incubation with 100 nM CRH for 10 min at 37 C. Given that IL-1ß pretreatment affected both basal and forskolin-induced adenylyl cyclase activity, results were calculated as percentage of forskolin-induced cAMP release, which was considered as maximum (100%) for each group (treated or untreated). Results are representative of six separate cell culture preparations. Each point is the mean ± SEM of four estimates. *, P < 0.05 compared with basal; +, P < 0. 05 compared with CRH-stimulated values in cells without IL-1ß pretreatment.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

The mechanisms regulating CRH-R1 alternative splicing are essentially unknown. Studies in keratinocytes suggest that environmental stimuli such as UV irradiation as well as intracellular messengers such as cAMP and phorbol esters can induce CRH-R1 splicing (23). Furthermore, CRH-R heterogeneity has been shown previously in human myometrial membrane extracts (24), and the functional activity of some receptor variants appeared to be differentially regulated by oxytocin (9, 10). Although the lack of suitable antibodies able to distinguish between different CRH-R1 variants does not allow additional investigations at the level of individual protein expression and functional response, these results strongly suggest that the CRH-R1 gene transcriptional activity and splicing is specifically targeted by the mechanisms involved in the onset of labor.

To investigate further the expression of CRH-R1, primary human myometrial cells were used, obtained from term human quiescent myometrial biopsies. This cellular system can provide useful information about the mechanisms regulating myometrial CRH-R expression and activity, although it cannot accurately reflect changes associated with the onset of labor because it is likely that cell-culturing conditions may alter cell phenotype. We were able for the first time to demonstrate uneven distribution of CRH-Rs in the plasma membrane. This finding strongly suggests "hotspots" of receptor expression, probably reflecting "confined" CRH-R signaling networks in specific areas. These experiments also showed significant cytoplasmic staining for CRH-R, potentially indicating newly synthesized unprocessed receptors, internalized mature CRH-R, or cytoplasmic forms of specific CRH-R variants. Moreover, our in vitro studies in myometrial cells identified IL-1ß as a potential regulator of CRH-R1 gene transcription and splicing pattern. IL-1ß, like many other proinflammatory cytokines, has been proposed to play important role in the onset of labor and the pathogenesis of infection-induced preterm labor (25). Our results suggest that IL-1ß can potentially target CRH-R1 gene transcription and splicing mechanisms targeting exon 6, but not exon 13, of the CRH-R1 gene; these interactions appeared to involve two members of the MAPK family of proteins, ERK1/2 and p38 MAPK. In a variety of cells, these kinases exert their effects through phosphorylation of p65 and modulation of the NF-B transcriptional activity (26). NF-B is a critical component of pathways mediating IL-1ß actions in human myometrium and other feto-maternal tissues (27) and increased p65 (RelA):p50 heterodimer DNA binding has been demonstrated in laboring myometrium and linked with increased transcriptional activation to specifically modulate changes in expression of genes critical for myometrial activation and contraction (28). Our results point toward an important role for NF-B in IL-1ß effects on CRH-R1 gene regulation and splicing, consistent with the presence of NF-B recognition elements in the CRH-R1 promoter (14). In our experimental paradigm, IL-1ß action induced phosphorylation of IB through an IKK-mediated mechanism that releases p65 (RelA) and allows its translocation to the nucleus (15). Other studies have showed that IL-1ß actions on myometrial cells can modulate endothelin B receptor but not endothelin A receptor mRNA and protein (29); thus, CRH-R1 IL-1ß interactions may be part of a much larger transcriptional modification in the myometrial cells.

Surprisingly, increased CRH-R1 gene transcription and generation of receptor splice variants was not associated with increased CRH signaling activity. On the contrary, prolonged exposure of cells to IL-1ß significantly impaired CRH-induced cAMP production, although the IL-1ß pretreatment significantly augmented basal adenylyl cyclase activity, in agreement with previous studies (30). It is likely that this is directly related to repression of the myometrial G_s gene by NF-B that has been reported recently (31). The possibility that IL-1ß pretreatment might induce expression of signaling-deficient variants of CRH-R1 such as R1c and R1d was excluded by our real-time PCR experiments. Interestingly, the myometrial IL-1ß/NF-B and cAMP/protein kinase A (PKA) signaling pathways can interact at multiple levels; exposure of myometrial cells to IL-1ß results in a significant up-regulation of cAMP-phosphodiesterase (PDE) 4, which is the predominant family of PDEs expressed in human myometrium (30) through a mechanism involving prostaglandin E₂ (PGE₂) production and subsequent cAMP augmentation. Also, myometrial p65 (RelA) appears to be specifically associated with PKAc (as well as IB), through an interaction that potentially involves the phosphorylation of p65 at serine-536 (28). This association might contributes to p65 inactive state until the cell is exposed to a p65 inducing stimuli (e.g. IL1-ß).

One of the main actions of IL-1ß in human myometrium involves the up-regulation of PTGS2 enzyme and increased production of PG, such as PGE₂ (19). Our previous studies (20) have shown that short (0.5–2 h) as well as prolonged (8–18 h) treatments with CRH can attenuate myometrial PGE₂ release, and only the prolonged effect of CRH can be inhibited by coincubation with IL-1ß. This coupled with the findings of the present study might suggest that IL-1ß acts to diminish the CRH-induced cAMP response through modulation of CRH-R1 gene transcription and splicing, up-regulation of PDE4, and/or down-regulation of G_s, thus implicating the myometrial cAMP/PKA pathway in the inhibition of PGE₂ synthesis and release.

In conclusion, we provide conclusive evidence that the onset of labor (preterm or term) is associated with increased transcription of the myometrial CRH-R1 gene and altered splicing events that down-regulate the pro-CRH-R1 mRNA encoding the R1ß variant but up-regulating receptor variants such as CRH-R1d, downstream of CRH-R1. IL-1ß appears to be one of the signals involved in the regulation of the CRH-R1 gene through a pathway involving activation of NF-B, the classical mediator of IL-1ß intracellular events, as well as at least two members of the MAPK family of proteins, ERK1/2 and p38 MAPK. Most importantly, IL-1ß actions lead to dampening of the CRH-induced cAMP response, an event that might contribute to the procontractile intracellular environment required for the onset of labor. It is attractive to speculate that up-regulation of functional CRH-R1s might lead to activation of alternative signaling cascades that might help in the transition of the uterus from a state of quiescence to one of increased contractility and active labor.

	Acknowledgments

 
We thank Drs. Mark Johnson and Dev Sooranna for useful discussions.

	Footnotes

 
This work was supported by a Wellcome Trust University Award (to D.K.G.) and a Warwick Private Hospitals Charitable Trust grant (to M.V.).

Disclosure Statement: The authors have nothing to disclose.

First Published Online April 12, 2007

Abbreviations: C_T, Threshold cycle; DAPI, 4',6'-diamidino-2-phenylindole; F-actin, filamentous actin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IKK, IB kinase; MEK, MAPK kinase; PDE, phosphodiesterase; PGE₂, prostaglandin E₂; PTGS2, prostaglandin-endoperoxide synthase 2; R, receptor; TBS, Tris-buffered saline; TBS-T, TBS containing 0.1% Tween 20.

Received January 22, 2007.

Accepted for publication April 2, 2007.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Challis JRG, Matthews SG, Gibb W, Lye SJ 2000 Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 21:514–550[Abstract/Free Full Text]
2. McLean M, Bisits A, Davies J, Woods R, Lowry P, Smith R 1995 A placental clock controlling the length of human pregnancy. Nat Med 1:460–463[CrossRef][Medline]
3. Grammatopoulos D, Hillhouse EW 1999 Role of corticotropin-releasing hormone in the onset of labour. Lancet 353:1546–1549[CrossRef]
4. Hillhouse EW, Grammatopoulos D 2001 Control of intracellular signalling by corticotropin-releasing hormone (CRH) in human myometrium. Front Horm Res 27:66–74[Medline]
5. Hillhouse EW, Grammatopoulos D, Milton N, Quartero H 1993 The identification of a human myometrial corticotropin-releasing hormone receptor which increases in affinity during pregnancy. J Clin Endocrinol Metab 76:736–741[Abstract]
6. Aggelidou E, Hillhouse EW, Grammatopoulos DK 2002 Up-regulation of nitric oxide synthase and modulation of the guanylate cyclase activity by corticotropin releasing hormone in cultured human pregnant myometrial cells. Proc Natl Acad Sci USA 99:3300–3305[Abstract/Free Full Text]
7. Mignot TM, Paris B, Carbonne B, Vauge C, Ferre F, Vaiman D 2005 Corticotropin-releasing hormone effects on human pregnant vs. nonpregnant myometrium explants estimated from a mathematical model of uterine contraction. J Appl Physiol 99:1157–1163[Abstract/Free Full Text]
8. Karteris E, Hillhouse EW, Grammatopoulos DK 2004 Expression of urocortin II (UCNII) and identification of distinct corticotropin-releasing hormone type-2 receptor (CRH-R2) signalling pathways regulating myosin light chain phosphorylation in pregnant myometrial cells. Endocrinology 145:890–900[CrossRef][Medline]
9. Grammatopoulos D, Hillhouse EW 1999 Activation of protein kinase C by oxytocin inhibits the biological activity of the human myometrial CRH receptor at term. Endocrinology 140:585–594[Abstract/Free Full Text]
10. Markovic D, Papadopoulou N, Teli T, Levine MA, Hillhouse EW, Grammatopoulos DK 2006 Differential responses of CRH receptor type 1 variants to PKC phosphorylation. J Pharmacol Exp Ther 319:1–11[Abstract/Free Full Text]
11. Hillhouse EW, Grammatopoulos DK 2006 The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27:260–286[Abstract/Free Full Text]
12. Grammatopoulos D, Dai Y, Chen J, Karteris E, Papadopoulou N, Easton AJ, Hillhouse EW 1998 Human CRH receptor: differences in subtype expression between pregnant and non-pregnant myometrium. J Clin Endocrinol Metab 83:2539–2544[Abstract/Free Full Text]
13. Grammatopoulos D, Dai Y, Randeva HS, Karteris E, Levine MA, Easton AJ, Hillhouse EW 1999 A novel spliced variant of the type 1 corticotropin-releasing hormone (CRH) receptor with a deletion in the 7th transmembrane domain present in the human pregnant term myometrium and fetal membranes. Mol Endocrinol 13:2189–2202[Abstract/Free Full Text]
14. Parham KL, Zervou S, Karteris E, Catalano RD, Old RW, Hillhouse EW 2004 Promoter analysis of human corticotropin-releasing factor (CRF) type 1 receptor and regulation by CRF and urocortin. Endocrinology 145:3971–3983[Abstract/Free Full Text]
15. Lindstrom TM, Bennett PR 2005 The role of nuclear factor B in human labour. Reproduction 130:569–581[Abstract/Free Full Text]
16. Belt AR, Baldassare JJ, Molnar M, Romero R, Hertelendy F 1999 The nuclear transcription factor NF-B mediates interleukin-1ß-induced expression of cyclooxygenase-2 in human myometrial cells. Am J Obstet Gynecol 181:359–366[CrossRef][Medline]
17. Bartlett SR, Sawdy R, Mann GE 1999 Induction of cyclooxygenase-2 expression in human myometrial smooth muscle cells by interleukin-1ß: involvement of p38 mitogen-activated protein kinase. J Physiol 520:399–406[Abstract/Free Full Text]
18. Pande V, Ramos MJ 2005 NF-B in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr Med Chem 12:357–374[Medline]
19. Sooranna SR, Engineer N, Loudon JAZ, Terzidou V, Bennett PR, Johnson MR 2005 The mitogen-activated protein kinase dependent expression of prostaglandin H synthase-2 and interleukin-8 messenger ribonucleic acid by myometrial cells: the differential effect of stretch and interleukin-1ß. J Clin Endocrinol Metab 90:3517–3527[Abstract/Free Full Text]
20. Grammatopoulos D, Hillhouse EW 1999 Basal and interleukin-1ß stimulated prostaglandin production from cultured human myometrial cells: differential regulation by corticotropin-releasing hormone. J Clin Endocrinol Metab 84:2204–2211[Abstract/Free Full Text]
21. Grammatopoulos D, Stirrat GM, Williams SA, Hillhouse, EW 1996 The biological activity of the corticotropin-releasing hormone receptor-adenylate cyclase complex in human myometrium is reduced at the end of pregnancy. J Clin Endocrinol Metab 81:745–751[Abstract]
22. Stevens MY, Challis JRG, Lye SJ 1998 Corticotropin-releasing hormone receptor subtype 1 is significantly up-regulated at the time of labour in the human myometrium. J Clin Endocrinol Metab 83:4107–4115[Abstract/Free Full Text]
23. Pisarchik A, Slominski AT 2001 Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J 15:2754–2756[Free Full Text]
24. Grammatopoulos D, Thompson S, Hillhouse EW 1995 The human myometrium expresses multiple isoforms of the corticotropin releasing hormone receptor. J Clin Endocrinol Metab 80:2388–2393[Abstract]
25. Muhle RA, Pavlidis P, Grundy WN, Hirsch E 2001 A high-throughput study of gene expression in preterm labor with a subtractive microarray approach. Am J Obstet Gynecol 185:716–724[CrossRef][Medline]
26. Viatour P, Merville MP, Bours V, Chariot A 2005 Phosphorylation of NF-B and IB proteins: implications in cancer and inflammation. Trends Biochem Sci 30:43–52[CrossRef][Medline]
27. Soloff MS, Cook Jr DL, Jeng Y-J, Anderson GD 2004 In situ analysis of interleukin-1-induced transcription of COX-2 and IL-8 in cultured human myometrial cells. Endocrinology 145:1248–1254[Abstract/Free Full Text]
28. Chapman NR, Europe-Finner GN, Robson SC 2004 Expression and deoxyribonucleic acid-binding activity of the nuclear factor B family in the human myometrium during pregnancy and labor. J Clin Endocrinol Metab 89:5683–5693.[Abstract/Free Full Text]
29. Breuiller-Fouché M, Morinière C, Dallot E, Oger S, Rebourcet R, Cabrol D, Leroy MJ 2005 Regulation of the endothelin/endothelin receptor system by interleukin-1ß in human myometrial cells. Endocrinology 146:4878–4886[Abstract/Free Full Text]
30. Oger S, Mehats C, Dallot E, Ferre F, Leroy MJ 2002 Interleukin-1ß induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E2- and cyclic adenosine 3',5'-monophosphate-dependent pathway. J Clin Endocrinol Metab 87:5524–5531[Abstract/Free Full Text]
31. Chapman NR, Smyrnias I, Anumba DO, Europe-Finner GN, Robson SC 2005 Expression of the GTP-binding protein (Gs) is repressed by the nuclear factor B RelA subunit in human myometrium. Endocrinology 146:4994–5002[Abstract/Free Full Text]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Markovic, D. Articles by Grammatopoulos, D. K. Search for Related Content PubMed PubMed Citation Articles by Markovic, D. Articles by Grammatopoulos, D. K.